Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Receivables: 2020-2024

Historic Receivables for IDEAYA Biosciences (IDYA) over the last 4 years, with Dec 2024 value amounting to $3,000.

  • IDEAYA Biosciences' Receivables fell 83.33% to $3,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $39,000, marking a year-over-year decrease of 99.47%. This contributed to the annual value of $3,000 for FY2024, which is 83.33% down from last year.
  • According to the latest figures from Q4 2024, IDEAYA Biosciences' Receivables is $3,000, which was down 85.00% from $20,000 recorded in Q3 2024.
  • IDEAYA Biosciences' Receivables' 5-year high stood at $6.7 million during Q3 2023, with a 5-year trough of $1,000 in Q2 2024.
  • Moreover, its 3-year median value for Receivables was $185,500 (2022), whereas its average is $1.0 million.
  • Its Receivables has fluctuated over the past 5 years, first surged by 238.80% in 2022, then crashed by 99.70% in 2024.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Receivables stood at $1.9 million in 2020, then crashed by 41.24% to $1.1 million in 2021, then tumbled by 80.87% to $211,000 in 2022, then tumbled by 91.47% to $18,000 in 2023, then tumbled by 83.33% to $3,000 in 2024.
  • Its Receivables stands at $3,000 for Q4 2024, versus $20,000 for Q3 2024 and $1,000 for Q2 2024.